Updates on treatment options in aspirin exacerbated respiratory disease

Abstract

Purpose of reviewThe aim is to describe why this review is timely and relevant. Acetylsalicylic acid exacerbated respiratory disease (AERD) is a clinically significant disease affecting approximately 7% of all asthmatics or around 1,400,000 persons in the United States alone. A large portion of these patients remain undiagnosed. This review summarizes up to date knowledge on the pathophysiology, treatment opinions and provides an expert opinion on how to approach the AERD patient. Recent findingsFindings describe the main themes in the literature covered by the article. Review of the current knowledge in terms of the key cells, cytokines/chemokines contributing to the acquired disease state of AERD. It also provides clinical approach toward the AERD patient with regards to current treatment options.

Aspirin desensitization in nonsteroidal anti-inflammatory exacerbated respiratory disease: The first prospective cohort in Chile

“…Available medical treatments include biological drugs and ASA desensitization. Biologics have proven to be effective and safe; however, their use is very limited due to their high cost ( 7 ). Desensitization consists of progressive administration of increasing doses of a drug to induce transient tolerance to it ( 8 ).…”